In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 275 of 373

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke	Interventional procedures guidance	11 February 2027
Percutaneous thrombectomy for intermediate-risk and high-risk acute pulmonary embolism	HealthTech guidance	7 April 2027
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]	Technology appraisal guidance	TBC
Pharmalgen for the treatment of bee and wasp venom allergy	Technology appraisal guidance	TBC
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]	Technology appraisal guidance	TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]	Technology appraisal guidance	TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]	Technology appraisal guidance	24 February 2027
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]	Technology appraisal guidance	17 September 2026
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]	Technology appraisal guidance	17 September 2026
Polyendocrine Metabolic Ovarian Syndrome (PMOS)	NICE guideline	9 December 2026
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]	Technology appraisal guidance	13 May 2027
Prostate cancer: diagnosis and management (update)	NICE guideline	17 December 2027
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]	Technology appraisal guidance	TBC
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]	Technology appraisal guidance	TBC
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]	Technology appraisal guidance	15 November 2017
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines [ID6356]	Technology appraisal guidance	8 July 2026
Renal cell carcinoma Pathways Pilot [ID6186]	Technology appraisal guidance	TBC
Renal sympathetic denervation for resistant hypertension	HealthTech guidance	TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]	Technology appraisal guidance	TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]	Technology appraisal guidance	TBC
Resminostat for maintenance treatment of advanced mycosis fungoides or Sezary syndrome [ID6478]	Technology appraisal guidance	TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]	Technology appraisal guidance	TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]	Technology appraisal guidance	16 December 2026

Results per page

10
25
50
All